Cationic liposomes as delivery systems for double-stranded PNA-DNA chimeras exhibiting decoy activity against NF-κB transcription factors

被引:45
作者
Borgatti, M
Breda, L
Cortesi, R
Nastruzzi, C
Romanelli, A
Saviano, M
Bianchi, N
Mischiati, C
Pedone, C
Gambari, R
机构
[1] Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy
[2] Univ Ferrara, Dept Pharmaceut Sci, I-44100 Ferrara, Italy
[3] Univ Perugia, Dept Pharmaceut Chem & Technol, I-06100 Perugia, Italy
[4] CNR, Inst Biostruct & Bioimages, I-80125 Naples, Italy
[5] Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy
关键词
PNA; decoy; liposomes; delivery;
D O I
10.1016/S0006-2952(02)01188-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Peptide nucleic acids (PNAs) have been recently proposed as useful molecules in pharmacogenetic therapy, especially due to the fact that they show a very high stability with respect to DNA and RNA. However, PNAs are not efficient decoy molecules, are characterized by negligible cell internalization and low solubility and are not suitable to be delivered by liposomes. With respect to the biological activity of PNA-based molecules, PDP deserve great consideration, due to the fact that they exhibit high levels of solubility, and are expected to be resistant to proteinases and exonucleases. In this manuscript we determined whether double-stranded molecules based on PNA-DNA chimeras containing NF-kappaB binding sites, exhibit decoy activity against NF-kappaB transcription factors. In addition, we determined whether they can be complexed by cationic liposomes. The results obtained demonstrated that hybrids based on PNA-DNA chimeras are powerful decoy molecules against NF-kappaB p52 transcription factor. In addition, we found that cationic liposomes can be proposed for in vitro delivery to target cells of these decoy molecules. The results presented in this paper are thus of practical importance, since the simplicity and the versatility of the cationic liposome technology have made cationic liposomes useful nonviral gene delivery systems for human gene therapy. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:609 / 616
页数:8
相关论文
共 31 条
[1]   Liposomal drug formulations - Rationale for development and what we can expect for the future [J].
Allen, TM .
DRUGS, 1998, 56 (05) :747-756
[2]   Faithful expression of a heterologous gene carried on an artificial macronuclear chromosome in Euplotes crassus [J].
Bender, J ;
Kämpfer, M ;
Klein, A .
NUCLEIC ACIDS RESEARCH, 1999, 27 (15) :3168-3172
[3]   A NUCLEIC-ACID TRIPLE-HELIX FORMED BY A PEPTIDE NUCLEIC-ACID DNA COMPLEX [J].
BETTS, L ;
JOSEY, JA ;
VEAL, JM ;
JORDAN, SR .
SCIENCE, 1995, 270 (5243) :1838-1841
[4]   Physico-chemical characterisation and transfection efficiency of lipid-based gene delivery complexes [J].
Birchall, JC ;
Kellaway, IW ;
Mills, SN .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 183 (02) :195-207
[5]   CRE-decoy oligonucleotide-inhibition of gene expression and tumor growth [J].
Cho-Chung, YS ;
Park, YG ;
Nesterova, M ;
Lee, YN ;
Cho, YS .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2000, 212 (1-2) :29-34
[6]  
CLUSEL C, 1995, GENE EXPRESSION, V4, P301
[7]   STABILITY OF PEPTIDE NUCLEIC-ACIDS IN HUMAN SERUM AND CELLULAR-EXTRACTS [J].
DEMIDOV, VV ;
POTAMAN, VN ;
FRANKKAMENETSKII, MD ;
EGHOLM, M ;
BUCHARD, O ;
SONNICHSEN, SH ;
NIELSEN, PE .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (06) :1310-1313
[8]   PNA HYBRIDIZES TO COMPLEMENTARY OLIGONUCLEOTIDES OBEYING THE WATSON-CRICK HYDROGEN-BONDING RULES [J].
EGHOLM, M ;
BUCHARDT, O ;
CHRISTENSEN, L ;
BEHRENS, C ;
FREIER, SM ;
DRIVER, DA ;
BERG, RH ;
KIM, SK ;
NORDEN, B ;
NIELSEN, PE .
NATURE, 1993, 365 (6446) :566-568
[9]   PEPTIDE NUCLEIC-ACIDS (PNA) - OLIGONUCLEOTIDE ANALOGS WITH AN ACHIRAL PEPTIDE BACKBONE [J].
EGHOLM, M ;
BUCHARDT, O ;
NIELSEN, PE ;
BERG, RH .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1992, 114 (05) :1895-1897
[10]   Peptide-nucleic acids (PNAs): A tool for the development of gene expression modifiers [J].
Gambari, R .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (17) :1839-1862